 Pliant Therapeutics

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Posters include data across biomarker, translation and clinical studies supporting development of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

Pliant Therapeutics has shown positive interim results in clinical trials for PLN-74809, including a Phase 2a trial for the treatment of IPF. Pliant has several advantages over its competitors, including a broad approach to targeting integrins and a diversified portfolio of drugs in development.

Pliant Therapeutics: Latest Financials Support Stable Investment In Future Growth

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors.

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related diseases. Its lead drug, bexotegrast, is being developed for Idiopathic Pulmonary Fibrosis (IPF). Bexotegrast is a small molecule dual selective inhibitor of αvß6 and αvß1 integrins, with the potential to reduce fibrosis while promoting tissue repair and regeneration.

Pliant Therapeutics' Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis

Phase 1 clinical study initiation expected in the second quarter of 2023 Phase 1 clinical study initiation expected in the second quarter of 2023

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the closing of its previously announced upsized underwritten public offering of 9,583,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,250,000 additional shares, at a price to the public of $30.00 per share. The aggregate gross proceeds from the offering were approximately $287.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Pliant. All shares of common stock were offered by Pliant.

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.

Why Pliant Therapeutics Stock Is Skyrocketing This Week

Patients with this condition have difficulty breathing due to a buildup of lung scar tissue. They have difficulty breathing due to built-up scar tissue in their lungs.

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.

Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced Ms. Lily Cheung as its Chief Human Resources Officer.

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $250.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Pliant. In addition, Pliant granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Pliant. The offering is expected to close on or about January 27, 2023, subject to the satisfaction of customary closing conditions.

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that it has commenced an underwritten public offering of $175.0 million of its common stock. In addition, Pliant expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this proposed offering will be sold by Pliant. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or the actual size or terms of the proposed offering.

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

Pliant Therapeutics unveiled promising results for a lung disease treatment on Monday, and PLRX stock rocketed into the stratosphere. The post An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50% appeared first on Investor's Business Daily.

An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50%

Pliant Therapeutics (NASDAQ: PLRX ) stock is taking off on Monday after releasing positive clinical trial data for bexotegrast. This is the company's treatment in development for patients suffering from idiopathic pulmonary fibrosis (IPF).

Why Is Pliant Therapeutics (PLRX) Stock Up 62% Today?

Shares of Pliant Therapeutics Inc. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients received the 320 milligram dose — the highest dose — and will continue to receive treatment for 24 weeks.

Pliant Therapeutics shares rally 75%

Bexotegrast demonstrated statistically significant increase  in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 41st Annual J.P. Morgan Healthcare Conference.

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Pliant Therapeutics' phase 2a data does not show a dose-dependent response in FVC. I discussed some of the other confusing issues here.

Pliant Therapeutics: Wait For More Data Clarity On Dose-Dependent Response In FVC

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that its lead drug candidate, bexotegrast (PLN-74809), an oral, once daily, dual-selective αvß6/αvß1 integrin inhibitor, has received Orphan Drug Designation from the European Medicines Agency (EMA) for the potential treatment of idiopathic pulmonary fibrosis (IPF). Bexotegrast is currently being tested in the INTEGRIS-IPF Phase 2a clinical trial in IPF. Pliant presented positive data from the first three dose cohorts of this randomized, double-blind, placebo-controlled trial in July and anticipates topline 12-week data from the 320 mg cohort of patients with IPF, in the first quarter of 2023.

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022 financial results.

News for Pliant Therapeutics Stock (PLRX)